Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
September 24, 2026 5:42 AM
Oppenheimer analyst Andreas Argyrides reiterated an Outperform rating and $70.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
